Author: Benzinga Newsdesk | November 06, 2025 07:37am
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is a 76 percent increase over losses of $(0.25) per share from the same period last year.